A dosimetric comparison of MammoSite® and ClearPath high-dose-rate breast brachytherapy devices

Dickler, Adam; Seif, Neil; Kirk, Michael C.; Patel, Mita B.; Bernard, Damian; Coon, Alan; Dowlatshahi, Kambiz; Das, Rupak K.; Patel, Rakesh R.

doi:10.1016/j.brachy.2008.07.006

« Previous Next »Brachytherapy
Volume 8, Issue 1 , Pages 14-18, January 2009

A dosimetric comparison of MammoSite^® and ClearPath high-dose-rate breast brachytherapy devices

Adam Dickler
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL
- Corresponding author. Adam Dickler, M.D., Department of Radiation Oncology, Little Company of Mary Hospital, 2800 West 95th Street, Evergreen Park, IL 60805, USA. Tel.: +1-708-229-5560; fax: +1-708-229-5378.
Neil Seif
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL
Michael C. Kirk
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL
Mita B. Patel
- Rush University Medical College, Rush University Medical Center, Chicago, IL
Damian Bernard
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL
Alan Coon
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL
Kambiz Dowlatshahi
- Department of General Surgery, Rush University Medical Center, Chicago, IL
Rupak K. Das
- Department of Human Oncology, University of Wisconsin, Madison. WI
Rakesh R. Patel
- Department of Human Oncology, University of Wisconsin, Madison. WI

Received 8 February 2008; received in revised form 30 July 2008; accepted 31 July 2008. published online 28 October 2008.

Abstract

Purpose

A new form of partial breast irradiation (PBI), ClearPath (CP) breast brachytherapy, has been introduced. We present our results of a dosimetric comparison of MammoSite^® (MS) and CP PBI.

Methods and Materials

The dimensions of the CP device were reconstructed onto the MS planning CT scans for 15 previously treated patients. The mean %V₁₀₀, %V₁₅₀, %V₂₀₀ (percent of the PTV that received 100%, 150%, and 200% of the prescription dose, respectively), ipsilateral breast %V₅₀ (percent of the ipsilateral normal breast that received 50% of the prescription dose), ipsilateral lung %V₃₀ (percent of the ipsilateral lung that received 30% of the prescription dose), the heart %V₅ (percent of the heart that received 5% of the prescription dose), and the maximum skin point dose per fraction were then determined for each patient using the two methods of balloon-based PBI.

Results

The mean %V₁₀₀ was 96.5% vs. 96.5%, the mean %V₁₅₀ was 42.1% vs. 42.9% (p=ns), and the mean V₂₀₀ was 11.4% vs. 15.2% (p<.05) for the MS and CP methods, respectively. The mean ipsilateral breast %V₅₀ was 19.8% vs.18.0% (p<.05), the mean ipsilateral lung %V₃₀ was 3.7% vs. 2.8% (p<.05), the mean heart %V₅ was 57.0% vs. 54.3% (p<.05), and the maximum skin point dose per fraction was 312.2 and 273.6cGy (p<.05) for the MS and CP methods, respectively.